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http://dx.doi.org/10.1016/j.stemcr.2017.08.004SUMMARYOur ultimate goal of in vitro derivation of Schwann cells (SCs) fromadult bonemarrow stromal cells (BMSCs) is such that theymay be used
autologously to assist post-traumatic nerve regeneration. Existing protocols for derivation of SC-like cells from BMSCs fall short in the
stability of the acquired phenotype and the functional capacity to myelinate axons. Our experiments indicated that neuro-ectodermal
progenitor cells among the human hBMSCs could be selectively expanded and then induced to differentiate into SC-like cells. Co-culture
of the SC-like cells with embryonic dorsal root ganglion neurons facilitated contact-mediated signaling that accomplished the switch to
fate-committed SCs.Microarray analysis and in vitromyelination provided evidence that the humanBMSC-derived SCswere functionally
mature. This was reinforced by repair andmyelination phenotypes observable in vivowith the derived SCs seeded into a nerve guide as an
implant across a critical gap in a rat model of sciatic nerve injury.INTRODUCTION
Although Schwann cells (SCs) have a major role as the
myelin-forming glial cells of the peripheral nervous system
(PNS), they switch on an axon-supportive program in
response to nerve injury. The injury-triggered reprogram-
ming engages SCs in myelin breakdown (Gomez-Sanchez
et al., 2015; Martini et al., 2008), neurotrophic factor pro-
duction (Brushart et al., 2013), guidance of axonal regrowth
(Rosenberg et al., 2014), and eventually axonal re-myelina-
tion (Chen et al., 2007). This repair mode of SCs is not
shared by the CNS counterpart, oligodendrocytes (Brosius
Lutz and Barres, 2014). The SCs have therefore been tapped
to assist post-traumatic nerve regeneration in the PNS
(Rodriguez et al., 2000) and CNS (Bachelin et al., 2005). To
take advantage of theuniqueplasticity of SCs, however, suf-
ficient numbers of SCs are required, ideally without having
to sacrifice a peripheral nerve for the graft.
This need is in part addressed by in vitro derivation of SC-
like cells (SCLCs) from bone marrow stromal cells (BMSCs)
with a cocktail of glia-inducing factors (GIFs) (Caddick
et al., 2006; Dezawa et al., 2001; Keilhoff et al., 2006).
The derived SCLCs however tended to be phenotypically
unstable and demonstrated limited capacity for re-myeli-
nation. This issue was overcome in an in vitro course by
which the SCLCs acquired competence and commitment
to the SC fate (Shea et al., 2010). Thereafter, the derived
SCs demonstrated capability to myelinate regrowing axons
not only in vitro but also in vivo (Ao et al., 2011).Stem Cell Repo
This is an open access article under the CHere, in anticipation of clinical application of BMSC-
derived SCs,we take a leap from the rat protocol to a human
protocol. Starting from human BMSCs (hBMSCs) express-
ing mesenchymal markers CD44, CD90, and CD105, we
propagated spheres with constituent cells expressing the
neuroglial progenitor markers, nestin and glial fibrillary
acidic protein (GFAP).With sphere cells in adherent culture
and soluble supplements in themedium, cells progressively
assumed the bi-/tri-polar morphology of SCLCs and ex-
pressed such markers as p75NTR and S100. Co-culture of
the hBMSC-derived SCLCs with rat dorsal root ganglion
(DRG) neurons provided proof of principle that juxtacrine
signaling between the neurons and SCLCs in co-culture ac-
complishes in vitro commitment of SCLCs to the SC fate.
Like the rat counterpart, hBMSC-derived SCs demonstrated
myelinating capacity both in vitro and in vivo.RESULTS
Characterization of hBMSCs
Primary hBMSCs adherent on tissue-culture plastic showed
thecharacteristicallyflattened,fibroblastic-likemorphology
(Figure S1A). The hBMSCs were positive for the mesen-
chymalmarkers,CD73,CD90, andCD105 (immunofluores-
cence; Figures S1B–S1D) at 94.6%, 92.0%, and 76.4%,
respectively (flow cytometry; Figures S1E–S1G). Following
adherent culture of the hBMSCs, 8.1% ± 2.2% (n = 6) were
nestin positive (Figures 1Aa and 1Ag) and none were GFAPrts j Vol. 9 j 1097–1108 j October 10, 2017 j ª 2017 The Authors. 1097
C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Directed Differentiation of hBMSCs to Fate-Committed SCs
(A) Neurospheres derived from hBMSCs. (a, b) Representative images of hBMSCs in adherent culture as viewed under epifluorescence
microscopy, being largely immunonegative for nestin and GFAP. (c) Representative image of spheres (arrowheads) on day 10 following
transfer of hBMSCs to non-adherent culture in sphere-forming medium. (d, e, f) Representative images of spheres continuing to day 14
in non-adherent, sphere-forming culture. At this stage, the neurosphere cells become largely immunopositive for nestin and GFAP (e, f,
and g), in contrast to the hBMSCs (g). **p < 0.01, hBMSC-derived neurosphere versus hBMSC. Scale bar, 100 mm. n = 6 independent
experiments.
(B) Differentiation of hBMSC-derived neurospheres into SCLCs. Phase-contrast images showing cells exiting from neurospheres on day 3 (a)
and day 5 (b) of adherent culture in a-MEM supplemented with GIFs and gradually assuming bi- and tri-polar morphologies typical of SCs in
culture on day 7 (c). Immunofluorescence for S100 and p75NTR among neurosphere-derived SCLCs in a-MEM supplemented with GIFs
(+GIFs) (d, e, merged in f) contrasting immunonegativity for the markers in DMEM/F12 with GIFs withdrawn (g, h, merged in i). Histogram
showing percentages of SCLCs immunopositive for the indicated markers in cultures supplemented with GIFs (+GIFs) versus those with GIFs
withdrawn (j). **p < 0.01, SCLC (+GIFs) versus SCLC (GIFs withdrawn). Scale bar, 100 mm. n = 6 independent experiments.
(C) Commitment of SCLCs to the SC fate following co-culture with DRG neurons. Phase-contrast images of hBMSC-dSCs in basal medium
without GIF supplementation or DRG neurons on day 3 (a) and day 7 (b). Phase-contrast image of a parallel-culture purified DRG neurons
(g). hBMSC-dSCs that are S100- and p75NTR-positive (c, d, merged in e) but TUJ1-negative (f), contrasting DRG neurons that are S100- and
p75NTR-negative (h) but TUJ1-positive (i). Histogram showing percentages of hBMSC-dSCs immunopositive for the indicated markers
versus null for purified DRG neurons (j). **p < 0.01, hBMSC-dSC versus DRG neuron. Scale bar, 100 mm. n = 6 independent experiments.positive (Figures 1Ab and 1Ag), suggesting the occurrence of
a neuroprogenitor subpopulation in the preparation.
Enrichment of Neuroprogenitor Cells in Sphere-
Forming Culture
Under sphere-forming conditions, the hBMSCs transi-
tioned into floating spheres, visible by day 10 (Figure 1Ac)
and expandable toR150 mm in diameter by day 14 (Figures
1Ad and S2). The increase in proportion of cells expressing
the neural stem/progenitor markers, nestin (80.2% ± 6.3%1098 Stem Cell Reports j Vol. 9 j 1097–1108 j October 10, 2017of the sphere cells, n = 6; Figures 1Ae and 1Ag) and GFAP
(75.7% ± 5.7% of the sphere cells, n = 6; Figures 1Af and
1Ag) was reinforced by western blot analysis of cell lysates
(Figure 2A). The results indicate successful propagation of
neuroprogenitors among the hBMSCs in sphere-forming
culture.
Directed Differentiation to SCLCs
Adherent culture of sphere cells in medium supplemented
with GIFs fostered transition to spindle-like cells in 3 days
Figure 2. Marker Protein Profiles of
hBMSCs, Neurosphere Cells, SCLCs, and
hBMSC-dSCs
(A) Western blot analysis for nestin and
GFAP in lysates of hBMSCs and hBMSC-
derived neurosphere cells (upper). Plots of
densitometric scans of band intensity as
normalized against that of b-actin (lower).
**p < 0.01, neurosphere cells versus hBMSC.
n = 6 independent experiments.
(B) Western blot analysis for p75NTR, S100,
and nestin in lysates of the respective
hBMSC-derived cell types (neurosphere
cells, SCLCs maintained in culture with GIF
supplementation (+GIFs) and then 3 days
after GIF withdrawal (GIFs withdrawn), and
hBMSC-dSCs) (upper). Plots of densito-
metric scans of band intensity as normal-
ized against that of b-actin (lower).
*p < 0.05, **p < 0.01, SCLC (+GIFs) and
SCLC (GIFs withdrawn) versus neurosphere
cells. ##p < 0.01, hBMSC-dSC versus
SCLC (GIFs withdrawn). n = 6 independent
experiments.(Figure 1Ba) and SC-like morphology with extended pro-
cesses in 5–7 days (Figures 1Bb and 1Bc). At this stage,
81.3% ± 5.4% (n = 6) of the cells were positive for S100 (Fig-
ures 1Bd and 1Bj) and 83.6% ± 6.5% (n = 6) were positive
for p75NTR (Figures 1Be and 1Bj); 66.9% ± 4.1% of the cells
co-expressed S100 and p75NTR (Figures 1Bf and 1Bj). How-
ever, these phenotypic features were not sustainable
following withdrawal of the GIFs from the cultures; in
3 days, the cells became fibroblast-like, and immunoposi-
tivities for the SC markers, S100 and p75NTR, were down
to 9.2% ± 1.6% (Figures 1Bg and 1Bj) and 11.8% ± 1.9%
(Figures 1Bh and 1Bj) respectively. Only 7.6% ± 1.1% of
the cells co-expressed S100 and p75NTR (Figures 1Bi and
1Bj). The GIFs could therefore not specify commitment
to the SC fate.
Commitment of SCLCs to SC Fate
As proof of principle that contact-mediated signaling
between sensory neurons and hBMSC-derived SCLCs is
necessary for transition to fate commitment, the SCLCs
were seeded onto purified rat DRG neuron networks. On
day 1 of co-culture, SCLCs remained fibroblast-like; from
day 7, they adopted bi-/tri-polar morphology with tapering
processes typical of SCs in culture (Figure S3). Neuronswere
detectable in proximity to the tapering SCLCs in the co-cul-
ture. In passaging the co-cultures, neurons did not survive
(TUJ1 negative; Figure 1Cf), resulting in mono-cultures
of SCLCs that persisted both in morphology (3 days, Fig-ure 1Ca; 7 days, Figure 1Cb) and marker expression as re-
vealed via immunocytochemistry (S100, 91.8% ± 7% of
cells; p75NTR, 95.3% ± 6.5%; both S100 and p75NTR,
84.9% ± 6% of cells) (n = 6; Figures 1Cc, 1Cd, 1Ce, and
1Cj) and western blot analysis (Figure 2B). Control cultures
of purified DRG neurons maintained in parallel showed no
signs of SCs in terms of marker expression (Figures 1Cg,
1Ch, and 1Cj) andmorphology (Figures S3D–S3F), whereas
the TUJ1-positive neurite network was clearly detectable
(Figure 1Ci). We therefore ruled out the possibility that
SCs observed in the co-culture arose from contaminating
glia in the DRG neuron preparation. The SCLC descen-
dants of the co-culture, having survived GIF withdrawal
and neuron removal, are therefore committed to the SC
fate and named as hBMSC-derived SCs (hBMSC-dSCs).
In VitroMyelination by hBMSC-dSCs
The hBMSC-dSCs were assessed for myelinating function
in co-culture with purified and semi-dissociated DRG neu-
rons. By day 14 in co-culture when hBMSC-dSCs were
observable in alignment with neurite bundles (Figures
3Aa and 3Ab), supplementation of the mediumwith ascor-
bic acid induced myelination. Myelin basic protein (MBP)-
positive segments were observable along neurite segments,
and these were regularly punctuated by MBP-negative
nodes (Figures 3Ac and 3Ad). Parallel co-cultures of the
DRG neuron network with hBMSCs (Figures 3Ba and
3Bb) or SCLCs (Figures 3Ca and 3Cb) did not show anyStem Cell Reports j Vol. 9 j 1097–1108 j October 10, 2017 1099
Figure 3. In Vitro Myelination of the DRG Neuritic Network by
hBMSC-dSCs
(A) Phase-contrast image showing hBMSC-dSCs (arrows) associated
with neurons as early as 48 hr in co-culture with the neuritic
network of purified DRG neurons in neuron maintenance medium
(a). Immunofluorescence for S100 and TUJ1 in a parallel culture
showing hBMSC-dSC (arrows) abutting on the neurites (b; right
panels, zoom-in views of the boxed areas i–iii). Following 14 days
of myelination induction, myelin-like segments (double-headed
arrows) were formed by hBMSC-dSCs along the neuritic networks as
shown by phase contrast (c) and immunofluorescence for MBP (d).
Scale bar, 100 mm.
1100 Stem Cell Reports j Vol. 9 j 1097–1108 j October 10, 2017MBP-positive segments. A representative field of view indi-
cated 87.6 ± 12.3 myelinated segments (n = 5, Figure 3D)
averaging 102.21 ± 19.73 mm per segment. Having demon-
strated myelinating capability of the hBMSC-dSCs in vitro,
we pursued evidence of such function of hBMSC-dSCs
in vivo.
hBMSC-dSCs as Source of Neurotrophic Factors
Preliminary to neurite growth studies, hBMSC-dSCs in
24-hr co-culture with Neuro2A cells were assessed for neu-
rotrophic factors produced into the medium. Compared
with co-cultures of hBMSCs or SCLCs with Neuro2A cells,
those of hBMSC-dSCs indicated significantly higher levels
of brain-derived neurotrophic factor (BDNF) (143.2 ± 6.8
versus 51.2 ± 4.4 or 60.5 ± 4.5 pg/mL), vascular endothelial
growth factor (VEGF) (4273 ± 280 versus 410 ± 21 or 453 ±
26 pg/mL), hepatocyte growth factor (HGF) (439.5 ± 40.4
versus 62.1 ± 12.4 or 78.0 ± 13.3 pg/mL), and nerve growth
factor (NGF) (163.1 ± 12.4 versus 23.1 ± 3.4 or 31.2 ±
4.2 pg/mL). For reference, basal levels ranged from 5 to
20 pg/mL in mono-cultures of Neuro2A cells (Figure 4A).
Concentrations were significantly lowered following treat-
ment of the cultures with neutralizing antibodies against
the respective neurotrophic factors (Figure 4A). The levels
of neurotrophic factors observable in day-1 cultures per-
sisted into day 2 (Figure 4B) when Neuro2A cells were as-
sessed for neurite growth patterns.
Neurotrophic Effects of hBMSC-dSCs
Neuro2A cells in co-culture with hBMSC-dSCs for 48 hr
(Figure 5Ad) showed increases in the number and length
of neurites when compared with parallel mono-cultures
of Neuro2A cells (Figure 5Aa) and co-cultures with
hBMSCs (Figure 5Ab) or SCLCs (Figures 5Ac, 5Ba, 5Bb,
and 5Bc). The significantly higher percentage of neurite-
bearing Neuro2A cells in co-cultures with hBMSC-dSCs
versus parallel mono-cultures of Neuro2A cells and co-cul-
tures with hBMSCs or SCLCs (Figure 5B) further suggest
enhanced survival. Treating the cultures with neutralizing
antibodies against BDNF, VEGF, HGF, NGF, singly or in
combination (Figure 5Ae), resulted in significant declines
in the percentage of neurite-bearing cells, the length of(B) hBMSCs in parallel co-culture with DRG neurons (arrows)
showed a fibroblast-like morphology (a) and failed to form MBP-
positive segments along neurites (b). Scale bar, 100 mm.
(C) SCLCs in parallel co-culture with the neuritic network of DRG
neurons (arrows) reverted to the myofibroblast phenotype (a) and
failed to form MBP-positive segments along neurites (b). Scale bar,
100 mm.
(D) Histogram showing myelinated segment counts in ten fields for
hBMSC-dSC versus hardly any for hBMSC (**p < 0.01) or SCLCs
(##p < 0.01). n = 5 independent experiments.
Figure 4. Neurotrophic Factors Secreted by hBMSC-dSCs
(A) Analysis for BDNF (a), VEGF (b), HGF (c), and NGF (d) in medium conditioned by Neuro2A cells (control) versus those in 24-hr co-culture
of Neuro2A with hBMSCs, SCLCs, or hBMSC-dSCs. Co-cultures were treated with (+) or without () a neutralizing antibody against the
indicated factor. The levels of BDNF, VEGF, HGF, and NGF in conditioned media from control, hBMSCs, SCLCs, and hBMSC-dSCs were
compared those following antibody treatment. *p < 0.05, **p < 0.01. n = 5 independent experiments.
(B) Analysis for BDNF (a), VEGF (b), HGF (c), and NGF (d) in medium conditioned by Neuro2A cells (control) versus media conditioned by
co-culture of Neuro2A with hBMSCs, SCLCs or hBMSC-dSCs on day 0, 1, or 2. **p < 0.01, day 1 or 2 versus day 0; ##p < 0.01, hBMSC-dSCs
versus hBMSCs or SCLCs. n = 5 independent experiments.the longest neurite, and the total neurite length per cell,
approaching those observed in co-cultures with hBMSCs
or SCLCs (Figure 5B). Neuro2A cells thus responded to
neurotrophic factors that were produced into the medium
of co-cultures with hBMSC-dSCs.Molecular Phenotype of hBMSC-dSCs
We then used microarrays to compare the gene expression
profiles of hBMSCs, SCLCs, hBMSC-dSCs, and adult human
SCs (hSCs, ATCC). Hierarchical clustering showed highly
similar gene expression profiles of hBMSC-dSCs and hSCsStem Cell Reports j Vol. 9 j 1097–1108 j October 10, 2017 1101
Figure 5. Neurite Outgrowth Mediated by
hBMSC-dSCs
(A) Representative images showing phase-
contrast views of Neuro2A cells (arrow-
heads) maintained in neat medium
(a, control) versus those in test co-culture
for 48 hr with hBMSCs (b), SCLCs (c), hBMSC-
dSCs (d), or hBMSC-dSCs with blocking an-
tibodies against BDNF, VEGF, HGF, and NGF
supplemented into the culture medium (e).
Scale bars, 50 mm.
(B) Histograms showing the percentage of
cells bearing at least one neuriteR the cell-
body diameter (a), length of the longest
neurite per cell (b), and total neurite length
per cell (c) of Neuro2A cells maintained in
neat medium (control) or in test co-culture
with hBMSCs, SCLCs, hBMSC-dSCs, or hBMSC-
dSCs with blocking antibodies against
BDNF, VEGF, HGF, and/or NGF. *p < 0.05,
**p < 0.01, hBMSC-dSC with or without
blocking antibodies versus hBMSC. #p <
0.05, ##p < 0.01, hBMSC-dSC with blocking
antibodies versus hBMSC-dSC without
blocking antibodies. n = 5 independent
experiments.as distinct from those of hBMSCs and SCLCs (Figure 6A).
This complements the properties of myelination and neu-
rotrophic factor production as evidence that the hBMSC-
dSCs were functionally viable. To further investigate the
differentiation status of the hBMSC-dSCs, Venn diagrams
depicting thedistributionof genesupregulated versus those
downregulated in SCLCs, hBMSC-dSCs, and the hSCs, in
comparisonwith those in hBMSCs, are shown in Figure 6B.
Only 357 genes (166 upregulated and 191 downregulated)
were significantly different between hBMSC-dSCs and
hSCs; 1,440 genes (692 upregulated and 748 downregu-
lated) were in common. In contrast, between SCLCs and
hSCs, up to 1,693 genes (806 upregulated and 887 downre-
gulated) were significantly different, and only 36 genes (16
upregulated and 20 downregulated) were in common (Fig-
ure 6B). Further pairwise comparisons revealed the similar
expression profiles between hBMSC-dSCs and hSCs,
whereas distinct gene expression profiles of hBMSC-dSCs
versus hBMSCs, hBMSC-dSCs versus SCLCs, and SCLCs
versus hSCs were evident (Figure 6C). A heatmap that tar-
gets expression of 64 genes identifiable with the different
stages of Schwann cell differentiation (Jessen and Mirsky,
2005; Krause et al., 2014) again showed highly similar
profiles of hBMSC-dSCs and hSCs, distinct from those of1102 Stem Cell Reports j Vol. 9 j 1097–1108 j October 10, 2017hBMSCs and SCLCs (Figure 6D). To verify the data obtained
via microarray analysis, quantitative real-time PCR (qRT-
PCR) was performed on nine differentially expressed genes
(Figure 6E). These includemarkers for neural crest stemcells
(AP2), Schwann cell differentiation marker (NOTCH1),
Schwann cell precursors (CDH19, SOX2), immature SCs
(SOX10, GFAP), non-myelinating SCs (S100), and myeli-
nating SCs (MBP, RPLP0). The qRT-PCR results reinforced
the microarray data, indicating that the hBMSC-dSCs are
highly similar to hSCs in marker mRNA profile.
Myelination of Regrowing Axons by hBMSC-dSCs
In Vivo
To demonstrate the capacity of hBMSC-dSCs for myelina-
tion in vivo, a nerve guide seeded with the cells was used
to bridge a critical gap in a rat model of sciatic nerve injury
in which host axons regrowing up to the mid-graft region
were myelinated by the seeded SCs and progeny (Ao et al.,
2011), By 8 weeks post graft, longitudinal sections made
in the mid-graft region indicated regrowing fibers, uni-
axially aligned, immunopositive for rat TUJ1 (Figure 7A),
and in alternation with layers/sheaths immunopositive
for human MBP (Figures 7B and 7C). In this mid-graft re-
gion, the rows of Hoechst-stained nuclei detectable along
Figure 6. hBMSC-dSCs Are Highly Similar to hSCs
(A) Hierarchical clustering of differentially expressed, overlapped genes illustrated in a heatmap. Blue and yellow indicate the highest and
lowest relative levels of expression, as defined by the color key.
(B) Venn diagrams depicting the numbers of genes that are downregulated (left) and upregulated (right) in SCLCs, hBMSC-dSCs, and hSCs,
in comparison with hBMSCs.
(C) Pairwise comparisons of expression profile between indicated cells. Blue dashed lines correspond to a 2-fold change. The differentially
expressed genes (red) are those that are 2-fold significantly different (p < 0.05).
(legend continued on next page)
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Figure 7. hBMSC-dSCs Myelinated Host
Axons by Being Seeded into a Nerve Guide
that Bridged a Critical Gap in a Rat Model
of Sciatic Nerve Injury
Longitudinal sections made in the mid-
region of the sciatic nerve guide reveal the
following.
(A) Uni-axially aligned fibers immuno-
positive for rat TUJ1, representative of
regrowing fibers.
(B) Rows of Hoechst-stained nuclei between
longitudinal layers immunopositive for hu-
man MBP.
(C) Myelin-ensheathed axons and rows of
peripherally located nuclei reminiscent of
those of Schwann cells in the merged images
of (A) and (B).
(D) The myelin structure was illustrated
in the TEM image of the transverse sec-
tion (enlarged in d*). Scale bars, 50 mm for
(A)–(C) and 200 nm for (D).the layers of myelin were reminiscent of the unique geom-
etry of SCs in Bu¨ngner regeneration tracks. A representative
transmission electron microscopy (TEM) image of a trans-
verse section in themid-graft region further indicatedmye-
linating SCs at the stage of forming compact myelin (Fig-
ures 7D and 7Dd*). Taken together, the results provide
in vivo evidence of functionally viable hBMSC-dSC subpop-
ulations, some in the repair phenotype guiding axonal re-
growth and others adopting the myelinating phenotype.(D) Heatmap of the microarray data for 64 genes associated with Sch
lowest relative levels of expression, as defined by the color key.
(E) qPCR validation of microarray data. GAPDH served as endog
sample.
1104 Stem Cell Reports j Vol. 9 j 1097–1108 j October 10, 2017DISCUSSION
Here, we aimed to derive fate-committed SCs from hBMSCs
such that sufficient numbers can be tapped on demand for
transplantation to improve the prospects of post-traumatic
regrowth and re-myelination of axons and recovery of
function. With use of stage-specific culture conditions, we
achieved the goal of generating abundant hBMSC-dSCs
that show morphological and molecular phenotypeswann cell differentiation. Blue and yellow indicate the highest and
enous standards, and data were normalized against an hBMSC
characteristic of SCs in culture. The hBMSC-dSCs supported
neurite growth via secretion of neurotrophic factors and
formed PNS-type myelin segments along neurites in in vitro
tests of function. The purified preparation of hBMSC-dSCs
canbekept in storage for at least 3months in liquidnitrogen
and tapped for use in transplantation studies.
Differentiation of the glial progenitors along the SC line-
age was fostered in adherent culture of sphere cells. Supple-
ments of basic fibroblast growth factor (bFGF), platelet-
derived growth factor (PDGF), b-heregulin, and forskolin
were as reported (Dezawa et al., 2001; Keilhoff et al.,
2006; Shea et al., 2010). Cells of bi-/tri-polar morphology
and expressing markers S100 and p75NTR resulted. These
early SCLCs were sustainable as long as the cocktail of
extrinsic factors was supplied to the culture. Similarly,
Schwann-like cells derived from human adipose-derived
mesenchymal stem cells underwent rapid reversion to
stem cell-like characteristics following withdrawal of the
GIFs (Faroni et al., 2016). Stable ex vivo differentiation to
maturity must be achieved before the derived SCLCs can
be considered safe for therapeutic applications.
SCs are developmentally derived from neural crest cells
that coalesce in DRGs following delamination from the
neural tube and migration along ventromedial routes (But-
ler and Bronner, 2015; Schwarz et al., 2009). It is yet unclear
how in the course of migration, neural crest cells acquire
competence and commitment to the sensory fate. Within
the DRGs, specification of peripheral glia is apparently
dependent on their association with cells that are
committed to neurogenesis (Keilhoff et al., 2006; Marmi-
gere and Ernfors, 2007;Woodhoo et al., 2009).We reasoned
that if neural crest cellsmiss theDRGs and instead enter the
developing vasculature, they can end up as residents of the
bone marrow and miss out the DRG neuronal signals. We
therefore sourced DRG neurons to provide BMSC-derived
SCLCs with the necessary signals for SC specification/
commitment. DRGneurons of E14/15 rats were readily har-
vested and purified for use in co-cultures with the hBMSC-
SCLCs.TheSCLCsprogressively acquired the SCphenotype
during co-culture and remained stably committed even in
subcultures in which extrinsic factors were withdrawn.
Neurons were no longer detectable after passage. The DRG
neurons were possibly triggered to re-enter the cell cycle
but failed to enter theMphase of the cell cycle, thus ending
in cell-cycle-related neuronal death (Herrup and Yang,
2007; Zhang et al., 2010). Naive SCLCs that had not been
in co-culture with embryonic rat DRG neurons lost the SC
phenotype. We conclude that contact-mediating signaling
via the incipient sensory neurons is key to directing BMSC-
derived SCLCs to SC specification and commitment.
The commitment to SCs is further demonstrated in vitro
with respect to myelinating and neurotrophic functions.
Myelination as a definitive function of mature SCs andMBP, and required for myelin compaction, is used as a
marker (Woodhoo et al., 2009; Cai et al., 2017). Our results
showed PNS-type MBP-positive segments among the prog-
eny of hBMSC-dSCs in co-culture with the neurite network
of purified DRG neurons. The indirect co-culture model of
hBMSC-dSCs and Neuro2A cells provided evidence that
the neurite growth-promoting response was attributable
to BDNF, VEGF, HGF, and NGF produced by hBMSC-dSC.
Indeed, BDNF, VEGF, HGF, and NGF produced by SCs after
injury are relevant to neuronal survival and axon regrowth
following injury (Cai et al., 2011; Taveggia et al., 2010). In
addition, the high correlation in gene expression profiles of
our hBMSC-dSCs with human SCs in contrast to that of
hBMSCs or SCLCs provides confidence that our hBMSC-
dSCs are of the human lineage. Within the microenviron-
ment of a nerve guide bridging across a critical gap in the
sciatic nerve of a ratmodel, the hBMSC-dSCs demonstrated
capacities for adopting both the repair phenotype for
guiding axonal regrowth and the myelinating phenotype
with expression of human MBP and formation of compact
myelin.
Taken together, this study demonstrates that the human
bone marrow harbors neuro-ectodermal progenitors that
can be enriched, expanded, and directed to differentiate
into functionally mature, fate-committed SCs. The results
hold promise for further development into an autologous
cell source for implantation as a treatment strategy for
nerve injuries or peripheral neuropathies.EXPERIMENTAL PROCEDURES
Culture of hBMSCs
Human bone marrow was obtained from consenting normal
donors 20–30 years of age by puncturing the posterior superior
iliac spine under sterile conditions (Lee et al., 2009) with informed
consent (Supplemental Experimental Procedures) as approved
by the Institutional Review Board, The University of Hong Kong.
Samples from six individuals were processed independently.
Induction of Neurospheres from hBMSCs
hBMSCs at passage 4 were seeded at 100,000 cells/mL in serum-
free sphere-forming medium consisting of 1:1 (v/v) DMEM/F12
and Neurobasal medium (Invitrogen) supplemented with bFGF
(40 ng/mL; Peprotech), epidermal growth factor (20 ng/mL; Pepro-
tech), and B27 (2%, v/v, Invitrogen) into ultra-low-attachment
poly(2-hydroxyethyl methacrylate)-coated culture plates (Corn-
ing). This non-adherent fraction was maintained for another
3 weeks. The spheres that formed were tested for nestin and GFAP
immunoreactivities asneuroprogenitormarkers. The sphere forma-
tion rate was assessed (Supplemental Experimental Procedures).
Differentiation of Neurosphere Cells into SCLCs
The neurospheres at passage 2 were seeded at 8–10 spheres/cm2
onto poly-L-lysine/laminin-coated culture dishes. Cultures wereStem Cell Reports j Vol. 9 j 1097–1108 j October 10, 2017 1105
maintained in glutamine-free a-MEM (Sigma) containing 10%
fetal bovine serum (FBS) and such GIFs as forskolin (FSK) (5 mM),
platelet-derived growth factor (PDGF)-AA (5 ng/mL), bFGF
(10 ng/mL), and b-heregulin (HRG) (200 ng/mL) for 2 weeks. Cells
immunoreactive for S100 and p75NTR at this stage were referred to
as SCLCs. These SCLCs were further cultured in basal medium
(DMEM/F12with 10%FBS) butwithout theGIFs to test for sustain-
ability of the SC phenotype.
Co-culture of SCLCs with Rat DRG Neurons
Rat DRG neurons were purified and maintained in culture (Shea
et al., 2010) (Supplemental Experimental Procedures). SCLCs were
seeded onto the DRG neuron culture at 3,000 cells/cm and main-
tainedas co-culture for 2weeks inglutamine-freea-MEMandNeuro-
basal medium (1:1, v/v) supplemented with FSK (2.5 mM), PDGF
(2.5 ng/mL), bFGF (5 ng/mL), b-HRG (100 ng/mL), NGF (5 ng/mL),
B27 (1%v/v), and FBS (5%). Following trypsinizationand subculture
inbasalmediumwithout theGIFs for at least 1week,neuronsdidnot
survive, whereas the surviving cells were all immunopositive for SC
markers; these cells were termedhBMSC-dSCs. Neuron cultures that
were not seeded with SCLCs were maintained in parallel under the
same conditions to exclude the possible contamination of co-
cultures with DRG-SCs. Control co-cultures were performed in
which a 5-mm-wide hydrophobic barrier prevented direct contact
between purified DRG neurons and SCLCs seeded to the left and
right of barrier, respectively (Shea et al., 2010).
In VitroMyelination
Myelination assay (Shea et al., 2010) was performed with hBMSC-
dSCs (80,000 cells) seeded onto DRG neuron cultures maintained
inneuronmaintenancemediumsupplementedwith10%FBS.Mye-
linationwas triggeredwith ascorbic acid (50 mg/mL, Sigma) added to
themedium. Twoweeks later, cultureswere assessed forMBP immu-
noreactivity along neurite segments. MBP-positive segments were
counted in ten randomly selected fields (magnification, 2003).
Co-culture with hBMSCs or SCLCs was set as the negative controls.
Immunofluorescence
Cellswere incubated (16hr, 4C)withoneof the primary antibodies
against CD 73 (mouse monoclonal, Abcam, cat. no. ab54217,
1:500), CD 90 (mouse monoclonal, Abcam, cat. no. ab181469,
1:200), CD105 (mouse monoclonal, Abcam, cat. no. ab2529,
1:200), nestin (mouse monoclonal, Abcam, cat. no. ab22035,
1:200), GFAP (mouse monoclonal, Abcam, cat. no. ab49874,
1:1,000), S100 (rabbit monoclonal, Abcam, cat. no. ab52642,
1:100), p75NTR (rabbit polyclonal, Abcam, cat. no. ab8874,
1:500), TUJ1 (rabbit polyclonal, Biolegend, cat. no. 802001,
1:1,000) and MBP (rabbit polyclonal, Abcam, cat. no. ab124493,
1:100). Cells were incubated (2 hr, 24C) with the appropriate sec-
ondary antibodies which included Alexa 488-conjugated goat
anti-mouse IgG (polyclonal, Abcam, cat. no. ab150113, 1:500),
Alexa 488-conjugated donkey anti-rabbit IgG (polyclonal, Abcam,
cat.no. ab150073,1:500),Alexa647-conjugateddonkeyanti-mouse
IgG (polyclonal, Abcam, cat. no. ab150107, 1:500), and Alexa
647-conjugated goat anti-rabbit IgG (polyclonal, Abcam, cat. no.
ab150079, 1:500). Nuclei were counterstained with 4,6-diamidino-
2-phenylindole (DAPI; Abcam). Cells were viewed under an1106 Stem Cell Reports j Vol. 9 j 1097–1108 j October 10, 2017Olympus IX71 inverted fluorescencemicroscope. For cell counting,
ten random fields were selected and a minimum of 500 cells were
counted in these fields. The number of marker-positive cells was
expressed as a percentage of the total number of cells counted.
Quantitative Real-Time Quantitative PCR
Cells were lysed with Trizol (Invitrogen). Total RNA was extracted
and reverse transcribed using SuperScript II First-Strand Synthesis
System (Invitrogen) according to the manufacturer’s instructions.
qRT-PCR was performed using the 9000HT instrument (Applied
Biosystems) and SYBR Premix EX Taq (Takara), following the man-
ufacturer’s instructions. Each sample was measured in triplicate.
Primer sequences are listed in Table S1.
Western Blot Analysis
Whole-cell lysates were prepared, and protein concentrations were
assayed (Pan et al., 2009). Equal amounts of proteinwere subjected
to SDS-PAGE and transferred to polyvinylidene difluoride mem-
brane (MilliporeCorp.).Membraneswere blocked and thenprobed
(16hr, 4C)with one of the antibodies againstGFAP (mousemono-
clonal, Abcam, cat. no. ab8975, 1:500), S100 (rabbit monoclonal,
Abcam, cat. no. ab52642, 1:1,000), p75NTR (rabbit polyclonal, Ab-
cam,cat.no. ab8874,1:500), ornestin (mousemonoclonal, Abcam,
cat. no. ab22035, 1:2,000) and b-actin (rabbit polyclonal, Abcam,
cat. no. ab8227, 1:1,000) as internal control. Then the membranes
were blotted with an appropriate horseradish-peroxidase-linked
secondary antibody. Electrochemiluminescencewas performed ac-
cording to the manufacturer’s instructions with the ChemiImager
5500 imaging system (Alpha Innotech Co.).
Neurite Outgrowth Analysis
Neuriteoutgrowthanalysis (Mahay et al., 2008; Park et al., 2010)was
performed with Neuro2A cells (1 3 105 cells per well) in MEM con-
taining 10% FBS for 16 hr and then in serum-free Neurobasal
mediumwith or without BDNF-, VEGF-, HGF-, and/or NGF-neutral-
izingantibody for8hr. Twenty-fourhours earlier, hBMSCs, SLCLs,or
hBMSC-dSCswere seeded at 13 105 cells per insert (1.0-mmpore size
cell-culture inserts, Falcon; BD Biosciences) and maintained in
culture for 48 hr. The inserts were then placed onto six-well plates
containing Neuro2A cells and maintained for another 48 hr. Cell-
free inserts (control) were incubated with Neuro2A cells under the
same conditions. Neurite outgrowth was assessed by the percentage
of process-bearing neurons, length of longest neurite, and total
neurite length per cell with use of SigmaScan Pro 5 software.
Enzyme-Linked Immunosorbant Assay
The conditioned medium from co-cultures of Neuro2A cells and
hBMSCs, SLCLs, or hBMSC-dSCs was collected and analyzed by
ELISA using the ChemiKine BDNF, VEGF, HGF, or NGF sandwich
ELISA kits (Chemicon, UK) according to the manufacturer’s proto-
col. The absorbance was measured at 450 nm (MultiskanMC plate
reader; Labsystems).
Microarrays
Total RNA was amplified and purified using a TargetAmp-
Nano Labeling Kit for Illumina Expression BeadChip (EPICENTRE,
Madison, USA) to yield biotinylated cRNA according to the
manufacturer’s instructions. After purification, the cRNA was
quantified using the ND-1000 Spectrophotometer (NanoDrop,
Wilmington, USA). cRNA samples were hybridized to each human
HT-12 v4.0 Expression Beadchip, according to the manufacturer’s
instructions (Illumina, Inc., San Diego, USA). Detection of array
signal was carried out using Amersham fluorolink streptavidin-
Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following
the bead array manual. Arrays were scanned with an Illumina
bead array Reader confocal scanner according to the manufac-
turer’s instructions. Raw data were extracted using the software Il-
lumina GenomeStudio v2011.1 (Gene Expression Module v1.9.0).
Array probes were transformed by logarithm and normalized
by the quantile method. Statistical significance of the expression
data was determined using the Independent LPE test and fold
change, in which the null hypothesis was that no difference exists
among groups. The false discovery rate was controlled by adjusting
the p value using the Benjamini-Hochberg algorithm. For a
DEG set, hierarchical cluster analysis was performed using com-
plete linkage and Euclidean distance as a measure of similarity.
Data analysis and visualization of differentially expressed genes
were conducted using R 3.1.2 (www.r-project.org).
Grafting Procedure
Grafting experiments were performed on sciatic nerves of pento-
barbital-anesthetized (60 mg/kg, intra-peritoneal) male Sprague-
Dawley rats (200–250 g). The rat was kept warm on a thermostat-
controlled heating pad (37C) throughout the surgery. The skin
on the posterolateral side of the left thigh was incised to expose
the sciatic nerve. A 5-mm segment of the nerve was excised at
mid-thigh level. The nerve stumps were bridged with a 16-mm
long chitosan conduit (2 mm in inner diameter, 0.3 mm in wall
thickness) such that the proximal and distal ends of the cut nerve
were telescoped 2mm into the conduit and then secured with pol-
ydioxanone sutures (PDS) to the wall of the conduit. The 12-mm
interstump gapwas pre-filled with (1) hBMSC-dSCs (1.53 105 cells
in 20 mL DMEM) mixed 1:1 (v/v) with Matrigel (BD) (test) versus
(2) 1:1 (v/v) with Matrigel in DMEM (control). The wound was
closed in two layers with 6-0 nylon sutures. The immunosup-
pressant cyclosporin A (Sigma) was administered to the animals
(10 mg/kg/day, subcutaneously). The animals were returned to
the cages with food and water ad libitum for 8 weeks before they
were killed. All surgical procedures were performed in strict accor-
dance with the Guide for the Care and Use of Laboratory Animal
(National Research Council, USA) and approved by the Committee




The experimental animals were killed with pentobarbital overdose
and then perfused with 4% paraformaldehyde. The regenerated tis-
sue cable was dissected out and post-fixed in 4% paraformaldehyde
for 2 hr before incubation in 30% sucrose overnight. Longitudinal
cryosections (100 mm) were prepared. The sections were permeabi-
lized and blocked with 0.3% Triton X-100 and 3% BSA (1 hr,
20C) and then incubated with primary antibodies (rabbit anti-rat
TUJ1,polyclonal, Biolegend, cat. no. 802001, 1:500;mouse anti-hu-manMBP,monoclonal, Abcam, cat. no. ab11223, 1:500; overnight,
4C) followed with the relevant secondary antibodies (1 hr, 20C).
Cell nuclei were counterstained with Hoechst 33258. For negative
control, isotype antibodies (rabbit IgG and mouse IgG, Invitrogen)
were used in lieu of the antigen-specific antibodies (Figure S4).
The stained sections were rinsed andmounted with mounting me-
dium (ibidi) for viewing and image capture under confocal micro-
scopy (Zeiss LSM780). For TEM, paraformaldehyde-fixed samples
were further treated with 1% osmium tetroxide and 1% uranyl ace-
tate and then embedded in Epon resin. Sections of 75–90 nm thick-
ness were picked up on formvar/carbon-coated 75-mesh Cu grids,
and stained for 20 s in 1:1 super-saturated uranyl acetate in acetone
followed by 0.2% lead citrate. Images were viewed and captured
under a Philips CM100 transmission electron microscope.Statistical Analysis
All experiments were repeated at least three times unless other-
wise indicated. Data are presented as means ± SD. Statistical anal-
ysis involved use of the Student t test. Statistical significance was
accepted at p < 0.05.ACCESSION NUMBERS
Microarray data in this article have been deposited in the GEO
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